SUBJECT
Title
Financing of health technologies
Type of instruction
lecture
Level
master
Faculty
Part of degree program
Credits
4
Recommended in
Semester 4
Typically offered in
Spring semester
Course description
- Introduction / Principles Transparency Directive
- Risk-sharing
- Risk-sharing II.
- Cost-containment policies
- Internal price referencing system
- External price referencing
- Generic and biosimilar drug policies
- Financing wholesalers and pharmacies
- Financing hospital technologies
- Financing clinical development of pharmaceuticals
- Financing research of new health technologies
- Biosimilar drug
Readings
- Council Directive 89/105/EEC of 21 December 1988 relating to the transparency of measures regulating the prices of medicinal products for human use and their inclusion in the scope of national health insurance systems
- http://eur-lex.europa.eu/LexUriServ/LexUriServ.do?uri=CELEX:31989L0105:en:HTML
- Garrison LP Jr, Towse A, Briggs A, de Pouvourville G, Grueger J, Mohr PE, Severens JL, Siviero P, Sleeper M. Performance-based risk-sharing arrangements-good practices for design, implementation, and evaluation: report of the ISPOR good practices for performance-based risk-sharing arrangements task force. Value Health. 2013. 16(5). 703-19.
- Carone G, Schwierz C, Xavier A. Cost-containment policies in public pharmaceutical spending in the EU. Economic Papers 461. 2012 http://ec.europa.eu/economy_finance/publications/economic_paper/2012/pdf/ecp_461_en.pdf
- Kalo Z, Abonyi-Toth Zs, Bartfai Z, Voko Z: Pitfalls associated with the therapeutic reference pricing practice of asthma medication, BMC Pulmonary Medicine, 2012 20. 12. 1. 35; 48.
- Kaló Z, Annemans L, Garrison LP. Differential pricing of new pharmaceuticals in lower income European countries. Expert Rev Pharmacoecon Outcomes Res, 2013. 13. 6. 735-741.
- Kaló Z, Holtorf AP, Alonso R, Shen J, Ágh T, Inotai A, Brixner D. Need for multi-criteria evaluation of generic drugs policies. Value in Health. 2015
- Kaló Z, Antal J, Pénzes M, Pozsgay Cs, Szepezdi Zs, Nagyjánosi L. Contribution of clinical trials to gross domestic product in Hungary. Croat Med J, 2014. 55. 5. 446-51.